BOSTON ( TheStreet) -- News of a drug's approval or rejection from the U.S. Food and Drug Administration can rock or kill a biotech stock's price. Here is an updated FDA calendar that shows 14 companies -- in chronological order -- with drugs facing FDA approval decisions through October 2010.
Cell Therapeutics (CTIC)
Drug/indication: Pixantrone for non-Hodgkin's lymphoma
Approval decision date: April 23An FDA advisory panel held on March 22 voted 9-0 to recommend against approval of pixantrone.